Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BupiKet: Bupivacaine + Ketamine for Hip/Femur Fracture
NCT03909594Phase 4Withdrawn
- Start
- Jan 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of ketamine in Musculoskeletal pain (2 arms). Primary endpoint: Time to first rescue analgesia post-regional nerve blockade at 24 hours. Planned start Jan 2022; status: withdrawn.
02
Drugs
ketamine
03
Conditions
Musculoskeletal pain
Beyond the preview
Go deeper on NCT03909594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03909594.